Harvard Catalyst Profiles

Jason Wasfy is director of outcomes research in the Massachusetts General Hospital Cardiology Division. His research broadly uses quasi-experimental statistical approaches as well as qualitative methods to understand comparative effectiveness of treatment strategies and the effects of health policies and novel forms of care delivery on clinical outcomes. His group also seeks to understand mechanisms of improving the resilience of cardiology care during the COVID-19 pandemic, and uses research techniques developed in economics and political science to understand the association of societal phenomena with public health outcomes and more rigorously assess comparative effectiveness of care delivery and treatment decisions.

Dr. Wasfy’s research has been funded both by the American Heart Association and National Institutes of Health as well as other sources and he was the recipient of the American Heart Association Quality and Outcomes Young Investigator Award in 2016. He has published over 160 peer-reviewed publications in academic journals, and he has mentored over 30 junior investigators. Dr. Wasfy sits on several committees of the American College of Cardiology and served as co-chair of the ACC telehealth roundtable. He also has served on key scientific committees of the American Heart Association and National Institutes of Health, and currently serves on the Lancet Commission on Atherosclerotic Heart Disease. He is currently the chair of the New England Comparative Effectiveness Public Affairs Council, the nation’s leading pharmaceutical price watchdog.

As a clinical cardiologist, Dr. Wasfy practices outpatient general cardiology as well as serves 8 weeks per year on several inpatient cardiology services including the cardiac intensive care unit.

Dr. Wasfy completed fellowships in cardiology and health policy and management at the MGH, where he was the Roman DeSanctis clinical scholar in cardiology in 2011 and served as chief fellow in cardiology. He received his undergraduate degree in chemical engineering from MIT, his MPhil from Oxford University where he studied as a Marshall Scholar, and his SM and MD degrees from Harvard.